Talis Biomedical (TLIS)
US Market

Talis Biomedical (TLIS) Income Statement


Talis Biomedical Income Statement

Last quarter (Q2 2023), Talis Biomedical's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q2, Talis Biomedical's net income was $-15.03M. See Talis Biomedical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 987.00K$ 4.81M$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
$ -1.07M$ -8.39M----
Gross Profit
$ -7.42M$ -8.39M----
Operating Expense
$ 260.52M$ 111.56M$ 191.82M$ 91.18M$ 26.70M$ 21.43M
Operating Income
$ -92.34M$ -119.95M$ -191.82M$ -91.18M$ -26.70M$ -21.43M
Net Non Operating Interest Income Expense
---$ 54.00K$ 42.00K$ 93.00K
Other Income Expense
$ -5.00M$ -6.94M$ -220.00K$ 54.00K$ -817.00K-
Pretax Income
$ -85.81M$ -113.01M$ -192.04M$ -91.13M$ -27.47M$ -21.34M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -85.81M$ -113.01M$ -192.04M$ -91.13M$ 26.38M$ -21.34M
Basic EPS
$ -13.17$ -4.24$ -8.48$ -4.63$ -13.42$ -9.46
Diluted EPS
$ -10.91$ -4.24$ -8.48$ -4.63$ -13.42$ -9.46
Basic Average Shares
$ 81.91M$ 26.63M$ 22.66M$ 19.68M$ 2.26M$ 2.26M
Diluted Average Shares
$ 81.91M$ 26.63M$ 22.66M$ 19.68M$ 2.26M$ 2.26M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 259.45M$ 103.17M$ 191.82M$ 91.18M$ 26.70M$ 21.43M
Net Income From Continuing And Discontinued Operation
$ -85.81M$ -113.01M$ -192.04M$ -91.13M$ -27.47M$ -21.34M
Normalized Income
$ -37.90M-$ -192.04M$ -91.13M$ -27.47M$ -21.34M
Interest Expense
$ -86.58M$ -113.01M$ -191.82M$ -91.18M$ -26.70M$ -21.43M
$ -78.75M$ -104.18M$ -190.24M$ -90.42M$ -25.97M$ -20.78M
Currency in USD

Talis Biomedical Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis